Lv3
276 积分 2024-04-18 加入
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
26天前
已完结
Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy
27天前
已完结
Effects of bisoprolol and verapamil in non-obstructive hypertrophic cardiomyopathy
27天前
已关闭
1837-P: Efficacy and Safety of DAPA/MET Fixed-Dose Combination (FDC) vs. Co-Administration (Co-ADM) in Chinese Patients with T2DM
1个月前
已关闭
以二甲双胍为基础的固定复方制剂治疗2型糖尿病专家共识
1个月前
已完结
2型糖尿病患者治疗过程中的临床惰性及其影响因素：一项多中心观察性研究结果
1个月前
已完结
Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024
1个月前
已完结
Cardiac Chamber‐Specific Regulation of Myosin Biochemical Super‐Relaxation and Auto‐Inhibition
2个月前
已完结
Mavacamten depresses human atrial contractility in the same EC50% range as human ventricle
2个月前
已完结
New and recurrent atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten
2个月前
已完结
皖公网安备34019202002308
